Left Menu
Development News Edition

Wall St Week Ahead-Investors look beyond drug makers as hunt for Covid-19 treatment heats up

Reuters | Updated: 23-05-2020 02:17 IST | Created: 23-05-2020 02:17 IST
Wall St Week Ahead-Investors look beyond drug makers as hunt for Covid-19 treatment heats up

Investors are diversifying bets in the healthcare sector, as the rush to develop treatments for Covid-19 has driven up prices for some pharmaceutical stocks. A record 48% of fund managers are overweight healthcare stocks, a BofA survey showed, and the S&P 500 healthcare sector is up nearly 34% since its March low. Hopes for a treatment have also sparked outsize rallies in the shares of companies such as Moderna and Inovio Pharmaceutcials, up 253% and 327% since the start of the year, respectively, as of Friday's close.

In recent weeks, news of potential treatments or vaccines to fight the pandemic have occasionally fueled swings in broader markets. Yet some fund managers believe lasting profits may be elusive for vaccine-makers, leading them to seek corners of the healthcare sector that could see longer-term benefits from the fight against coronavirus.

Large pharmaceutical companies such as Johnson & Johnson and GlaxoSmithKline Plc have said they plan to make any successful vaccine available at cost, though they could reap profits later if a seasonal shot is needed . Multiple treatments could also divide the market between many players, investors said. "There's the question of 'Does anyone really make a lot of money on this?," said Larry Cordisco, co-portfolio manager of the Osterweis Fund.

Signs of progress on potential treatments could bolster the case for a quicker economic recovery and further fuel the rally that has boosted the S&P 500 around 30% from its late March lows. In the next two weeks, Gilead Sciences is expected to announce results of clinical studies of its potential coronavirus treatment remdesivir for patients with moderate symptoms of Covid-19. Pfizer has said it expects to release safety data for initial human testing of experimental vaccine by the end of May. Cordisco is looking further afield. One of the companies he owns is medical device maker Danaher Corp, which manufactures a rapid Covid-19 test the FDA approved in March. Its shares are up 3.1% since the start of the year.

"If you're looking for where the profits might be in the chain, it’s somebody like that who is going to benefit. They can cash in the whole way," Cordisco said. Alessandro Valentini, portfolio manager at Causeway Capital Management, said his firm is looking for value opportunities as the healthcare sector becomes more expensive, trading now at 22.9 times trailing earnings, slightly more than the 21.9 multiple of the S&P 500 index as a whole.

He is staying away from potential vaccine producers in favor of companies such as Takeda Pharmaceutical Co Ltd. Japan's largest pharmaceutical company said this month it could start clinical trials as early as July for a COVID-19 treatment based on antibodies from blood of recovered patients. "This is a company that will be part of the solution and can buy a world class business for a significant discount to what we think the fair value is," Valentini said. Its shares are down nearly 6.5% for the year to date.

Mike Caldwell, a portfolio manager of the Driehaus Event Driven Fund, said his fund is focusing on supply chains of vaccine production rather than the drug companies themselves. He is betting on companies such as Roche Holding and Abbott Laboratories, which have large diagnostics businesses that will likely be a part of any future COVID-19 treatment.

He is also bullish on smaller companies such as Luminex Corp , which received an FDA emergency use authorization for its COVID-19 diagnostic test. Shares are up 36% year to date. "With so many players who have meaningful resources, it's hard to predict what the ultimate market share of any one approach will be," he said.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

China: A savior for emerging markets or a poison pill?

... ...

Future of Urban Planning: Artificial Intelligence guiding the way

Advances in emerging technologies like Artificial Intelligence and Machine Learning can help us understand our cities better and derive useful insights from real-time data collected through automated models....

Videos

Latest News

Soccer-Rooney ends playing career to become Derby manager

Former Manchester United and England striker Wayne Rooney has called time on his playing career after being named as manager of Derby County, the Championship club said on Friday. The 35-year-old had been managing the club on an interim bas...

Govt launches PMKVY 3.0 to empower youth with new-age skills to boost employability

The government on Friday launched the third phase of its flagship skilling scheme Pradhan Mantri Kaushal Vikas Yojana PMKVY 3.0 in a bid to empower the countrys youth with employable skills by making over 300 skill courses available to them...

Luus to lead SA women as ODI, T20I squads announced for Pak series

Cricket South Africa CSA on Friday named an 18-player squad to take on Pakistan women in the three ODIs and as many T20Is as they look ahead to making a strong comeback to international cricket. The first of the three-match one-day series w...

6.3 crore domestic air passengers in 2020, 56 pc lower than 2019: DGCA

A total of 6.3 crore domestic passengers travelled by air last year, 56.29 per cent lower than 2019, Indian aviation regulator DGCA said on Friday.The impact of the coronavirus pandemic continues to be felt on the Indian aviation sector as ...

Give Feedback